|
?:abstract
|
-
Background: We have previously demonstrated in a prospective, multinational study that patients with heart failure (HF) with preserved LV ejection fraction (HFpEF) had lower mortality than those with reduced ejection fraction (HFrEF) over 2 years of follow up We report here the longer-term clinical outcomes for patients in the NZ-arm of this study Method: Patients were those >18 years with clinical diagnosis of HF enrolled at 4 centres in NZ Patients were assessed at enrolment with extensive phenotypic characterisation The main outcome measures were death from any cause, and death or HF readmission Cox proportional hazards model was used to assess outcome for patients with HFpEF and those with mid-range EF (HFmrEF) compared with those with HFrEF, including age and sex, medical history, aetiology, creatinine and NTproBNP in the model Results: 940 patients were followed for minimum of 4 years Patients with HFpEF were older (74 vs 66yrs), more commonly women (44% vs 21%) and had higher blood pressure (128 vs 116mmHg) compared with those with HFrEF Over the 4 years of follow up patients with HFpEF had a lower risk of death compared to patients with HFrEF, (112 vs 143/1000 patient years) however there was a similar risk of combined end-point of death or HF admission in all EF-subgroups (57 4% vs 51 5% vs 54 9%) (Figure) [Formula presented] Conclusion: This national data demonstrates that over the 4-year follow up that patients with HFpEF has a lower risk of death than those with HFrEF However the burden of HF readmissions was high and similar across all EF subgroups
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}